Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.
Okabe J, Kodama T, Sato Y, Shigeno S, Matsumae T, Daiku K, Sato K, Yoshioka T, Shigekawa M, Higashiguchi M, Kobayashi S, Hikita H, Tatsumi T, Okamoto T, Satoh T, Eguchi H, Akira S, Takehara T. Okabe J, et al. Among authors: daiku k. J Exp Clin Cancer Res. 2023 Oct 9;42(1):262. doi: 10.1186/s13046-023-02831-w. J Exp Clin Cancer Res. 2023. PMID: 37814340 Free PMC article.
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T, Ikezawa K, Kawamoto Y, Hirao T, Higashi S, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Ohkawa K. Yamai T, et al. Among authors: daiku k. Curr Oncol. 2022 Apr 11;29(4):2644-2649. doi: 10.3390/curroncol29040216. Curr Oncol. 2022. PMID: 35448190 Free PMC article.
Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Yamai T, Ikezawa K, Hiraga E, Kawamoto Y, Hirao T, Higashi S, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Takada R, Nakabori T, Fukutake N, Uehara H, Fujita M, Ohkawa K. Yamai T, et al. Among authors: daiku k. PLoS One. 2022 Mar 1;17(3):e0264653. doi: 10.1371/journal.pone.0264653. eCollection 2022. PLoS One. 2022. PMID: 35231078 Free PMC article.
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Ashida R, Akita H, Takahashi H, Teshima T, Ohkawa K. Takada R, et al. Among authors: daiku k. Cancers (Basel). 2021 Sep 21;13(18):4733. doi: 10.3390/cancers13184733. Cancers (Basel). 2021. PMID: 34572960 Free PMC article.
14 results